Adalimumab is a biologic medication to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD). It is a targeted therapy that works by inhibiting tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation and immune response. Adalimumab marketed under the brand name Humira, and it has become widely used due to its effectiveness and tolerability.